OS OSCR Oscar Health, Inc. Loading... : Bullish and Bearish Analyst Opinions

Author discloses a current long position in OSCR, indicating personal conviction in the healthcare stock.

CEO insider purchase of $12M in OSCR shares, now worth $30M; factual event noted with approving tone.

Author took partial profits on OSCR near $13 average but retains most shares, while holding HIMS without selling, reflecting mixed conviction.

Buy OSCR expecting continued rotation into healthcare from saturated hardware; Q1 momentum and upcoming Q2 catalyst support $40 target.

Rotate from overvalued tech to undervalued healthcare based on record relative valuation disparity; author holds OSCR and UNH and expects further outperformance.

The author's comment that OSCR looks phenomenal is a hot take without an explicit position or forward call, so it is treated as a watch.

Watch OSCR: author reacts positively with LFG to a bullish parent view, but does not disclose an active position or concrete trade in this reply.

Author discloses current long position in OSCR alongside LMND, with the shared thesis that tech-driven insurers can disrupt the entrenched, century-old insurance industry.

Author discloses being up over 100% on their Oscar position after increasing it at $14.19, signaling strong conviction and a bullish outlook.

Price observation only, no directional view or catalyst from speaker.

Buy OSCR with a $30 price target supported by a bottom-up valuation: $20B projected revenue at 2.5% net margin implies at least $10B market cap at a 0.5x sales multiple, suggesting meaningful upside from current levels.

Ozark sarcastically suggests OSCR and MOH would be best based on flawed logic, noting OSCR already bounced, without a clear directional view.

The tweet expresses a bullish outlook on Molina Healthcare and Oscar Health, indicating positive sentiment towards these managed care and health insurance companies.

Speaker reviews $OSCR: market cap same as 2021/2023 but 2x revenue, massive scale gains, clear path to profitability — undervalued thesis.

MOH and OSCR are rising despite negative news context.

The author anticipates a Democratic midterm victory will lead to increased healthcare spending, benefiting Molina Healthcare and Oscar Health.

The user is expressing a desire to buy more shares of Molina Healthcare and Oscar Health at lower prices.

The author anticipates a market rally for healthcare and clean energy stocks following a Democratic sweep.

Author identifies OSCR as the 'ACA pure play insurer' with the 'biggest convexity to ACA credit reversal' based on historical price reaction. Despite a Wells Fargo sell rating, the policy catalyst is

1. THE FACT: Identified $11 as a "DEEP Discount" price for OSCR and "IPR" (implied purchase/investment). 2. THE BRIDGE: The speaker is investing at this price, indicating a belief in significant long-term appreciation from this "discount" level. 3. THE VERDICT: OSCR at $11 is considered a deep discount for a long-term play.

1. THE FACT: Identifying "LIFE Changing Fibonacci DEEP Discounts" at specific price points for these tickers, planning to buy for "6 figures and LEAPS". Also planning Cash Secured PUTS for income. 2. THE BRIDGE: These specific price levels are considered deep discounts based on Fibonacci analysis, presenting a buying opportunity for significant long-term returns, potentially enhanced by selling cash-secured puts. 3. THE VERDICT: Buy these tickers at the specified "deep discount" Fibonacci levels using LEAPS for long-term appreciation, and generate income by selling Cash Secured Puts.